Alzheimer’s Disease: Causes, Biomarkers, and Treatments — Prof Karl Herrup | Reason & Wellbeing 39

In the first part of this conversation (   • Alzheimer's Disease: Why We're Wrong About...  ), Greg spoke with Karl about the biological processes that drive Alzheimer's disease development. In this part, they continue down that path but then turn to how to use biomarkers to identify people who are at high risk of the disease. They wrap up by discussing treatments for Alzheimer's, and whether it's possible to repurpose existing medications that were developed to treat other ailments. As always, you can also find Reason & Wellbeing on all major podcasting platforms, and it's on Apple Podcasts here: https://podcasts.apple.com/gb/podcast... Enjoy, and let us know your thoughts in the comments below! People and resources featured in this episode: Karl Herrup, PhD. Find out more about Karl’s work here: https://www.pstp.pitt.edu/people/karl... Karl is on LinkedIn here:   / karl-herrup-920a3a2a7   Greg Potter, PhD. Follow Greg on Instagram here:   / gregpotterphd   Follow Greg on LinkedIn here:   / gregpotterphd   Book: How Not to Study a Disease: The Story of Alzheimer's https://www.amazon.com/How-Not-Study-... Video: Professor Becci Strawbridge on lithium    • Lithium and Mood, Cognition, and Longevity...   Video: Professor Darren Candow on creatine and brain health    • Creatine and Sleep, Brain Health, Long COV...   Journal article: Karl’s paper illustrating problems with two monoclonal antibodies https://pubmed.ncbi.nlm.nih.gov/38951... Journal article: Karl’s paper questioning the monoclonal antibody Donanemab https://pubmed.ncbi.nlm.nih.gov/38830... Time codes: 00:00 — DNA damage, brain ageing, and Alzheimer's disease risk 06:58 — Pathogens, immune activity, and Alzheimer's disease risk 09:45 — Sleep, the glymphatic system, and Alzheimer's disease risk 12:05 — Lysosome dysfunction, lipofuscin, and and Alzheimer's disease risk 15:53 — Iron, ferroptosis, and Alzheimer's disease risk 17:54 — Could blood donation reduce dementia risk? 23:47 — Biomarkers of dementia (e.g., phospho-tau 217): are there any good ones? 29:47 — Treatments for Alzheimer's disease: monoclonal antibodies, multiple sclerosis drugs, NSAIDs, GLP-1 receptor agonists 39:36 — Hormone replacement therapy and differences in Alzheimer's between men and women 42:16 — Could sildenafil (Viagara) help prevent dementia? 43:58 — Might psychedelics reduce risk of dementia? 46:11 — Lithium, creatine, and melatonin as supplements to mitigate dementia 47:53 — Difficulties identifying treatments for Alzheimer's 50:07 — Where to follow Karl's work Disclaimer: This video is for informational purposes only. The video does not constitute the practice of medicine or any other professional healthcare service. The use of information on this video or materials linked from this video is exclusively at the listener’s own risk. The contents of this video are not intended to substitute for professional medical advice, diagnosis, or treatment. Viewers should not wait to obtain or disregard medical advice for any medical conditions they have and should seek the assistance of their healthcare professionals for such conditions. Under no circumstances shall Greg Potter, Greg Potter PhD Limited, or any guests or contributors to the podcast be responsible for damages arising from the use of the contents of this video.